← Back to Search

Psychosocial Support for Glioblastoma

N/A

Recruiting

Led By Laura S. Porter, PhD

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients who self-report a diagnosis of glioblastoma

Age >18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up end of study (4-months)

Awards & highlights

Study Summary

This trial aims to help caregivers and patients cope with glioblastoma by providing psychosocial support.

Who is the study for?

This trial is for adults over 18 years old who have been diagnosed with glioblastoma and can communicate in English. It's designed to help patients and their family caregivers.Check my eligibility

What is being tested?

The study is testing a psychosocial support program aimed at providing emotional and social support to those affected by glioblastoma, including the patients themselves as well as their family caregivers.See study design

What are the potential side effects?

Since this intervention involves psychosocial support, there are no direct medical side effects like you'd expect from medication or surgery. However, discussing sensitive issues may cause emotional discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with glioblastoma.

Select...

I am older than 18 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ end of study (4-months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~end of study (4-months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and end of study (4-months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants who complete post-intervention assessment

Number of participants who complete study participation

Participants' satisfaction with treatment

Secondary outcome measures

Anxiety and depressive symptoms as measured by the Hospital Anxiety and Depression Scale (HADS)

Caregiving efficacy as measured by the caregiver inventory

Functional well-being as measured by the Functional Assessment of Cancer Therapy - General (FACT-G)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Psychosocial Support InterventionExperimental Treatment1 Intervention

The psychosocial support intervention includes components such as logistical and practical support and self-care, strategies to manage cognitive changes, as well as strategies for effective communication when coping with glioblastoma.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Glioblastoma FoundationUNKNOWN

Duke UniversityLead Sponsor

2,364 Previous Clinical Trials

3,420,602 Total Patients Enrolled

39 Trials studying Glioblastoma

1,621 Patients Enrolled for Glioblastoma

Laura S. Porter, PhDPrincipal InvestigatorDuke University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total cohort size of this experiment?

"Affirmative, the information on clinicaltrials.gov shows that this medical trial is actively recruiting patients; it was originally posted on November 3rd 2023 and last updated 29 days later. 40 participants are required from a single centre to complete the study."

Answered by AI

Are there opportunities to participate in this experiment presently available?

"According to the clinicaltrials.gov listing, this investigation is currently recruiting participants and has been since November 3rd 2023 when it was initially posted; its details were last updated on November 29th 2023."

Answered by AI

What positive results is this clinical trial seeking to achieve?

"The primary objective of this trial, assessed over a period of four months, is to determine the number of participants who complete post-intervention assessment. Secondary outcomes include assessing patients' level of anxiety and depression with the Hospital Anxiety and Depression Scale (HADS), general distress levels by means of the Distress Thermometer, and caregiving efficacy via the Caregiver Inventory."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Glioblastoma Psychosocial Support Program

2023. "Glioblastoma Psychosocial Support Program". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06038604.